The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Specific Probiotics for Chronic Kidney Disease: A Review


Affiliations
1 Medical Services and Pharmacovigilance, Centaur Pharmaceuticals Pvt. Ltd.,
2 Kibow Biotech Inc., PA, USA
     

   Subscribe/Renew Journal


Chronic kidney disease (CKD) is a global health issue with a high economic cost to health systems and one of the risk factor for cardiovascular disease (CVD). All stages of CKD are associated with decreased quality of life. CKD is usually asymptomatic until later stages. Probiotics are living micro-organism very well known for a role they in the prevention and reduction of risk factors for several diseases and are also capable of enhancing certain vital physiological functions. A normal human digestive tract contains about 400 types (strains) of probiotic bacteria that control and reduce the growth of harmful bacteria and promote a healthy digestive system. The application of probiotics to kidney health is an emerging area of medicine that has only recently come into attention of scientists. In CKD patients there is a build-up of poisonous wastes in the bloodstream due to the overloaded and impaired kidneys. Certain probiotic microorganisms can utilize urea, uric acid, creatinine and other toxins as nutrients for growth which helps eliminate them as fecal matter. Probiotic organisms transform the colon into a blood cleansing organ in cases where kidney fails to remove toxins from blood. Thus probiotics are new hope for CKD patients and can be used to delay progression of disease. We aim to compile the data of various researches and clinical trials being conducted to evaluate benefits of probiotics in CKD patients. Acknowledgements and Disclosures: This article is written with the medical writing support from Centaur Pharmaceuticals Pvt Ltd, the marketers of Renadyl™ in India (sourced from Kibow Biotech, USA).

Keywords

Chronic Kidney Disease (CKD), Probiotics and Uremic Toxins.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Hill, Nathan R., et al. “Global prevalence of chronic kidney disease–a systematic review and meta-analysis.” PloS one11.7 (2016): e0158765.

  • Prabhu, Ravindra, et al. “Status of chronic kidney disease (CKD) in India–A narrative review.” International Education and Research Journal 2.1 (2016): 121-124.

  • http://www.kidneyfund.org/kidney-disease/chronic-kidneydisease-ckd/

  • Webster, Angela C., et al. “Chronic kidney disease.” The Lancet 389.10075 (2017): 1238-1252.

  • Thomas, Robert, Abbas Kanso, and John R. Sedor. “Chronic kidney disease and its complications.” Primary care: Clinics in office practice 35.2 (2008): 329-344.

  • Vassalotti, Joseph A., et al. “Practical approach to detection and management of chronic kidney disease for the primary care clinician.” The American journal of medicine 129.2 (2016): 153-162.

  • Zirker, Lindsey. “Probiotic use in chronic kidney disease patients.” Journal of Renal Nutrition 24.6 (2014): e47-e49.

  • Pandey, Kavita R., Suresh R. Naik, and Babu V. Vakil. “Probiotics, prebiotics and synbiotics-a review.” Journal of food science and technology 52.12 (2015): 7577-7587.

  • Arora, M., and A. Baldi. “Regulatory categories of probiotics across the globe: a review representing existing and recommended categorization.” Indian journal of medical microbiology 33.5 (2015): 2

  • Ranganathan, Natarajan. “Concept and Potential of Enteric Dialysis®-Treating the Cause of Dysbiosis and not the Symptoms in Chronic Kidney Diseases (CKD).” J Nephrol Ther 5.209 (2015): 2161-0959

  • Ranganathan, N., et al. “Review of Health Status and Level of Satisfaction of Customers with CKD Using Renadyl™: Results of a Survey.” International Journal of Medical and Applied Sciences 3.3 (2014): 183-205.

  • Natarajan, Ranganathan, et al. “Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients.” BioMed research international 2014 (2014).

  • Ranganathan, N., et al. “Dose escalation, safety and impact of a strain-specific probiotic (Renadyl) on stages III and IV chronic kidney disease patients.” Journal of Nephrology & Therapeutics 3.141 (2013): 2161-0959.

  • Ranganathan, Natarajan, et al. “Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.” Advances in therapy 27.9 (2010): 634-647.

  • Ranganathan, Natarajan, et al. “Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada.” Current medical research and opinion 25.8 (2009): 1919-1930.

  • Borges, Natália A., et al. “Probiotic supplementation in chronic kidney disease: a double-blind, randomized, placebocontrolled trial.” Journal of Renal Nutrition 28.1 (2018): 28-36.

  • Guida, Bruna, et al. “Effect of a short-course treatment with synbiotics on plasma p-cresol concentration in kidney transplant recipients.” Journal of the American College of Nutrition 36.7 (2017): 586-591.

  • Pavan, Malleshappa. “Influence of prebiotic and probiotic supplementation on the progression of chronic kidney disease.” Minerva urologica e nefrologica= The Italian journal of urology and nephrology 68.2 (2016): 222-226.

  • Rossi, Megan, et al. “Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial.” Clinical Journal of the American Society of Nephrology (2016): CJN-05240515.

  • Viramontes-Hörner, Daniela, et al. “Effect of a symbiotic gel (Lactobacillus acidophilus+ Bifidobacterium lactis+ inulin) on presence and severity of gastrointestinal symptoms in hemodialysis patients.” Journal of Renal Nutrition 25.3 (2015): 284-291.

  • Wang, I-K., et al. “The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial.” Beneficial microbes 6.4 (2015): 423-430

  • Campieri, Claudio, et al. “Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration.” Kidney international 60.3 (2001): 1097-1105.

  • Cruz-Mora, José, et al. “Effects of a symbiotic on gut microbiota in Mexican patients with end-stage renal disease.” Journal of Renal Nutrition 24.5 (2014): 330-335.

  • Simenhoff, M. L., et al. “Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus.” Mineral and electrolyte metabolism 22.1-3 (1996): 92-96.


Abstract Views: 282

PDF Views: 0




  • Specific Probiotics for Chronic Kidney Disease: A Review

Abstract Views: 282  |  PDF Views: 0

Authors

Mayuresh Dilip Kiran
Medical Services and Pharmacovigilance, Centaur Pharmaceuticals Pvt. Ltd.,
Pooja Gharat
Medical Services and Pharmacovigilance, Centaur Pharmaceuticals Pvt. Ltd.,
Monali Vakharia
Medical Services and Pharmacovigilance, Centaur Pharmaceuticals Pvt. Ltd.,
Natarajan Ranganathan
Kibow Biotech Inc., PA, USA

Abstract


Chronic kidney disease (CKD) is a global health issue with a high economic cost to health systems and one of the risk factor for cardiovascular disease (CVD). All stages of CKD are associated with decreased quality of life. CKD is usually asymptomatic until later stages. Probiotics are living micro-organism very well known for a role they in the prevention and reduction of risk factors for several diseases and are also capable of enhancing certain vital physiological functions. A normal human digestive tract contains about 400 types (strains) of probiotic bacteria that control and reduce the growth of harmful bacteria and promote a healthy digestive system. The application of probiotics to kidney health is an emerging area of medicine that has only recently come into attention of scientists. In CKD patients there is a build-up of poisonous wastes in the bloodstream due to the overloaded and impaired kidneys. Certain probiotic microorganisms can utilize urea, uric acid, creatinine and other toxins as nutrients for growth which helps eliminate them as fecal matter. Probiotic organisms transform the colon into a blood cleansing organ in cases where kidney fails to remove toxins from blood. Thus probiotics are new hope for CKD patients and can be used to delay progression of disease. We aim to compile the data of various researches and clinical trials being conducted to evaluate benefits of probiotics in CKD patients. Acknowledgements and Disclosures: This article is written with the medical writing support from Centaur Pharmaceuticals Pvt Ltd, the marketers of Renadyl™ in India (sourced from Kibow Biotech, USA).

Keywords


Chronic Kidney Disease (CKD), Probiotics and Uremic Toxins.

References